Literature DB >> 15290918

Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children.

Sandeep K Gupta1, Joseph F Fitzgerald, Joseph M Croffie, Marian D Pfefferkorn, Jean Pappas Molleston, Mark R Corkins.   

Abstract

BACKGROUND: Our purpose was to study the concordance of serological tests for inflammatory bowel disease with clinical diagnosis established by traditional testing in children.
METHODS: All children seen in our division who had IBD Diagnostic System (ie, pANCA, ASCA IgA, and ASCA IgG) performed over a 21-month period (June 1998 to February 2000) were identified. Their medical records were reviewed for basic demographics, test results (endoscopy, histology, and radiology), IBD Diagnostic System results, and patient symptoms/medications. Results of the IBD Diagnostic System were compared with several patient characteristics including age, sex, absence/presence of symptoms, medication use, disease activity and duration.
RESULTS: One hundred seven patients were divided into 6 groups based on clinical diagnosis and IBD Diagnostic System results. The sensitivity, specificity and +/- predictive values of the IBD Diagnostic System for ulcerative colitis were 69.2, 95.1, 90.0, and 87.1%, respectively, and for Crohn's disease were 54.1, 96.8, 90.9, and 80.8%, respectively. Overall, the results of the IBD Diagnostic System were concordant with the clinical diagnosis in 76 of the 107 (71%) patients.
CONCLUSIONS: In our experience, the specificity of IBD Diagnostic System is better than the sensitivity; the sensitivity is better for ulcerative colitis than Crohn's disease (69.2% vs 54.1%). The low sensitivity, especially for Crohn's disease, precludes the possibility that the IBD Diagnostic System can replace traditional studies when evaluating for inflammatory bowel disease. Though we do not exclude inflammatory bowel disease solely by IBD Diagnostic System results, it is reassuring to note that all patients without clinical evidence of inflammatory bowel disease also had negative IBD Diagnostic System results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15290918     DOI: 10.1097/00054725-200405000-00010

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  9 in total

Review 1.  Relevance of serologic studies in inflammatory bowel disease.

Authors:  Gwenola Vernier; Boualem Sendid; Daniel Poulain; Jean-Frédéric Colombel
Journal:  Curr Gastroenterol Rep       Date:  2004-12

2.  Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology?

Authors:  James Markowitz; Subra Kugathasan; Marla Dubinsky; Ling Mei; Wallace Crandall; Neal LeLeiko; Maria Oliva-Hemker; Joel Rosh; Jonathan Evans; David Mack; Anthony Otley; Marian Pfefferkorn; Ron Bahar; Eric Vasiliauskas; Ghassan Wahbeh; Gary Silber; J Antonio Quiros; Iwona Wrobel; Justin Nebel; Carol Landers; Yoanna Picornell; Stephan Targan; Trudy Lerer; Jeffrey Hyams
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

Review 3.  Clinical Utility of Biomarkers in IBD.

Authors:  Gerhard Rogler; Luc Biedermann
Journal:  Curr Gastroenterol Rep       Date:  2015-07

4.  The histopathological approach to inflammatory bowel disease: a practice guide.

Authors:  Cord Langner; Fernando Magro; Ann Driessen; Arzu Ensari; Gerassimos J Mantzaris; Vincenzo Villanacci; Gabriel Becheanu; Paula Borralho Nunes; Gieri Cathomas; Walter Fries; Anne Jouret-Mourin; Claudia Mescoli; Giovanni de Petris; Carlos A Rubio; Neil A Shepherd; Michael Vieth; Rami Eliakim; Karel Geboes
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

5.  Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn's disease.

Authors:  Michael Logan; Mary MacKinder; Clare Martha Clark; Aikaterini Kountouri; Mwansa Jere; Umer Zeeshan Ijaz; Richard Hansen; Paraic McGrogan; Richard K Russell; Konstantinos Gerasimidis
Journal:  BMC Gastroenterol       Date:  2022-05-23       Impact factor: 2.847

Review 6.  New serological markers in pediatric patients with inflammatory bowel disease.

Authors:  Márta Kovács; Katalin Eszter Müller; Mária Papp; Péter László Lakatos; Mihály Csöndes; Gábor Veres
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

7.  Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis.

Authors:  Vishal Anand; Anthony S Russell; Ross Tsuyuki; Richard Fedorak
Journal:  Can J Gastroenterol       Date:  2008-01       Impact factor: 3.522

Review 8.  Inflammatory bowel diseases: the paediatric gastroenterologist's perspective.

Authors:  Jean-Pierre Hugot; Marc Bellaiche
Journal:  Pediatr Radiol       Date:  2007-09-25

9.  Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study.

Authors:  S Desplat-Jégo; C Johanet; A Escande; J Goetz; N Fabien; N Olsson; E Ballot; J Sarles; J J Baudon; J C Grimaud; M Veyrac; P Chamouard; R L Humbel
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.